I

Incyclix Bio

6 employees

Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Pharmaceutical
Therapeutics
Health Care

Date founded

2020

Funding rounds raised

Total raised

$30M

from 3 investors over 3 rounds

I

Incyclix Bio raised $30M on March 31, 2022

Investors: Eshelman Ventures, LLC and RA Capital Management, L.P.

I

Incyclix Bio raised $6M on August 6, 2020

Investors: Eshelman Ventures, LLC

FAQ